These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8074984)

  • 1. Blood safety proposals.
    Oncology (Williston Park); 1994 Jun; 8(6):57-8. PubMed ID: 8074984
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic and biochemical factors affecting product consistency: introduction to the issues.
    Seamon KB
    Dev Biol Stand; 1992; 76():63-7. PubMed ID: 1478357
    [No Abstract]   [Full Text] [Related]  

  • 3. International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Jun; 70(125):37861-2. PubMed ID: 15988855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Conference on Harmonisation; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Sep; 63(182):50244-9. PubMed ID: 12269373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological products; blood specificity designators; technical amendments--FDA. Final rule; technical amendments.
    Fed Regist; 1994 May; 59(87):23636-7. PubMed ID: 10184096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The problem with the double-edged solution.
    Czap A
    Altern Med Rev; 2009 Jun; 14(2):96-8. PubMed ID: 19594219
    [No Abstract]   [Full Text] [Related]  

  • 8. Introduction to the issues: viral vectors and potential problems in their use.
    Klinman DM
    Dev Biol Stand; 1992; 76():299-300. PubMed ID: 1478347
    [No Abstract]   [Full Text] [Related]  

  • 9. Well-characterized biotechnology products: evolving to meet the needs of the 21st century.
    Zoon KC
    Dev Biol Stand; 1998; 96():3-8. PubMed ID: 9890510
    [No Abstract]   [Full Text] [Related]  

  • 10. Medical devices of human origin.
    Williams D
    Med Device Technol; 2001 Apr; 12(3):8, 10-1. PubMed ID: 11547687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. US biotech prepares to fight generic biologics.
    Reid B
    Nat Biotechnol; 2002 Apr; 20(4):322. PubMed ID: 11923820
    [No Abstract]   [Full Text] [Related]  

  • 12. Application of good manufacturing practice regulations to investigational biologic products.
    Goebel PW
    J Parenter Drug Assoc; 1980; 34(5):348-51. PubMed ID: 6905865
    [No Abstract]   [Full Text] [Related]  

  • 13. "Regulation of biological products".
    Fehnel PO
    Proc Inst Med Chic; 1972 Nov; 29(6):220. PubMed ID: 4678553
    [No Abstract]   [Full Text] [Related]  

  • 14. The transmissible spongiform encephalopathy agents: concerns and responses of United States regulatory agencies in maintaining the safety of biologics.
    Asher DM
    Dev Biol Stand; 1999; 100():103-18. PubMed ID: 10616181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Informed consent and living human cells.
    Maloney DM
    Hum Res Rep; 2002 Jul; 17(7):3. PubMed ID: 12731490
    [No Abstract]   [Full Text] [Related]  

  • 16. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Jun; 66(112):31146-65. PubMed ID: 11725786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies.
    Asher DM
    Dev Biol Stand; 1999; 99():41-4. PubMed ID: 10404874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Making sure biologicals are safe.
    Hecht A
    FDA Consum; 1977; 11(6):21-6. PubMed ID: 10304996
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.